UF

UFP Technologies, Inc.

UFPTHealthcareNASDAQ

Medical Devices

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$602.8M
+19.5% YoY
Net Income
$68.3M
+15.8% YoY
EBITDA
$111.5M
+16.4% YoY
Free Cash Flow
$53.6M

Scan Results

Daily timeframe
2 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Jul 11 MACD Negative CrossoverHistogram -2.2653, negative momentum
Jul 10 MACD Negative CrossoverHistogram -0.6214, negative momentum
About UFP Technologies, Inc.

Headquartered within the healthcare sector, UFP Technologies, Inc. focuses on Medical Devices services and products. UFP Technologies, Inc., together with its subsidiaries, designs and manufactures solutions for medical devices, sterile packaging, and other engineered custom products in the United States. Valued at $1.90B, UFPT is a small-cap name in its sector. The company provides protective drapes for robotic surgery, patient handling and comfort, advanced wound care, infection prevention, disposables for surgical and endoscopic procedures, packaging for medical devices, orthopedic implants, components for cardiac implants, dispenser coils for catheters, and biopharma drug manufacturing.

Key stats
Market Cap$1.90B
P/E (TTM)27.98
Fwd P/E21.04
EPS$8.79
Beta1.07
52W Change+7.5%
ROE17.2%
Analysis

On the balance sheet, UFPT has $20.0M in cash with $156.1M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $53.6M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 17.2% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 8.8% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $353.8M (2022) to $602.8M (2025), reflecting a 70% increase over the period.

Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. No single metric tells the full story. Reviewing UFPT's risk profile alongside its fundamentals and technical indicators provides a more complete picture.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance is an educational tool. Past performance does not guarantee future results.PrivacyTerms